Tryton Medical Obtains $20,000,000 Series D Round

  • Feed Type
  • Date
    9/14/2010
  • Company Name
    Tryton Medical
  • Mailing Address
    1000 Park Forty Plaza Durham, MA 27713
  • Company Description
    Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent – leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery.
  • Website
    http://www.trytonmedical.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    This Series D financing enables us to conduct our U.S. pivotal trial and drive product adoption internationally.
  • M&A Terms
  • Venture Investor
    Arnerich Messina & Associates, Inc.
  • Venture Investor
    PTV Sciences
  • Venture Investor
    Spray Venture Partners
  • Venture Investor
    Rivervest Venture Partners

By posting a comment, you agree to our terms and conditions.